Nicholas Saccomano
Vermögen: 42 964 $ am 31.07.2026
Vermögen: 42 964 $ am 31.07.2026
Nicholas A. Saccomano is currently President, Chief Executive Officer & Director at OnKure Therapeutics, Inc. He is also a Director at Kestrel Therapeutics, Inc., Modulo Bio, Inc., Think Bioscience, Inc. (since 2022), and BioLoomics, Inc. Formerly, Dr. Saccomano was Chief Executive Officer & Director at OnKure, Inc. from 2023 to 2024.
He served as Director at KromaTid, Inc. and Latigo Biotherapeutics, Inc. He was Senior Vice President at Pfizer Inc. from 1984 to 2008.
In 2008, he was Chief Scientific Officer at Bend Research, Inc. He worked as a Venture Adviser at Torrey Pines Investment, Inc. From 2019 to 2022, he was Chief Science Officer at Array BioPharma, Inc. From 2009 to 2014, he was Chief Technology Officer at SomaLogic Operating Co., Inc. Education includes a doctorate from the Graduate School of Arts & Sciences at Columbia University and an undergraduate degree from The State University of New York, conferred in 1980.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0.03% | 07.08.2026 | 11’247 ( 0.03% ) | 42 964 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
Think Bioscience, Inc.
Think Bioscience, Inc. BiotechnologyHealth Technology Develops small-molecule drugs | Direktor/Vorstandsmitglied | 06.09.2022 |
BioLoomics, Inc.
BioLoomics, Inc. BiotechnologyHealth Technology Provides novel drug screening services to analyze drug action and toxicity | Direktor/Vorstandsmitglied | - |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology development company | Direktor/Vorstandsmitglied | - |
Modulo Bio, Inc.
Modulo Bio, Inc. BiotechnologyHealth Technology Discovers treatments and digital platform that harness the neuron immune system for the benefit of patients and their families | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2022 |
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology Operates as a protein biomarker discovery and clinical diagnostics company | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2014 |
Bend Research, Inc.
Bend Research, Inc. Pharmaceuticals: MajorHealth Technology Provides drug delivery and formulation development technologies | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2008 |
| PFIZER INC. | Corporate Officer/Principal | 01.05.2008 |
| LATIGO BIOTHERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 14 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops & commercializes biopharmaceutical drugs | Health Technology |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing epigenetic therapies for the treatment of cancer | Health Technology |
KromaTid, Inc.
KromaTid, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology Operates as a protein biomarker discovery and clinical diagnostics company | Health Technology |
The State University of New York
The State University of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bend Research, Inc.
Bend Research, Inc. Pharmaceuticals: MajorHealth Technology Provides drug delivery and formulation development technologies | Health Technology |
Torrey Pines Investment, Inc.
Torrey Pines Investment, Inc. Investment ManagersFinance Torrey Pines Investment invest in companies located in the United States. The firm targets companies operating in the field of biotechnology and pharmaceutical sectors. It provides financing for early stage capital requirement. It acts as lead investor and also makes co-investments. | Finance |
Graduate School of Arts & Sciences (Columbia University )
Graduate School of Arts & Sciences (Columbia University ) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioLoomics, Inc.
BioLoomics, Inc. BiotechnologyHealth Technology Provides novel drug screening services to analyze drug action and toxicity | Health Technology |
Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage company that develops non-opioid pain medicines | Health Technology |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology development company | Commercial Services |
Modulo Bio, Inc.
Modulo Bio, Inc. BiotechnologyHealth Technology Discovers treatments and digital platform that harness the neuron immune system for the benefit of patients and their families | Health Technology |
Think Bioscience, Inc.
Think Bioscience, Inc. BiotechnologyHealth Technology Develops small-molecule drugs | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen